Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: A phase II study

Anti-Cancer Drugs

Volumn 18, Issue 6, 2007, Pages 687-692

  Nisticò, Cecilia ^a   Bria, Emilio ^a   Cuppone, Federica ^a   Fornier, Monica ^b   Sperduti, Isabella ^a   Carpino, Armando ^a   Pace, Andrea ^a   Cognetti, Francesco ^a   Terzoli, Edmondo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Epirubicin; G CSF; Metastatic breast cancer; Paclitaxel; Weekly

Indexed keywords

CHLORPHENIRAMINE; DEXAMETHASONE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL;

EID: 34548331840     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328035f863     Document Type: Article

References (35)

1. Jemal A, Siegel R,Ward E, Murray T, XU J, Smigal C, et al. Cancer statistics 2006. CA Cancer J Clin 2006; 56:106-130.
2. Beahrs OH, Henson DE, Hutter RVP (editors). Manual for staging of cancer. 3rd ed. Philadelphia: Lippincott; 1998. pp. 145.
3. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31 510 women. J Clin Oncol 1998; 1:3439-3460.
4. Perez EA. Paclitaxel in breast cancer. Oncologist 1998; 3:373-389.
5. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by 3-h infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87:1169-1175.
6. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, et al. Phase II trial of paclitaxel by 3-h infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13:2575-2581.
7. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13:1152-1159.
8. Bria E, Giannarelli D, Felici A, Peters WP, Nistico' C, Vanni B, et al. Taxanes with anthracyclines as first line chemotherapy for metastatic breast cancer: pooled analysis of 2805 patients. Cancer 2005; 103:672-679.
9. Seidman AD, Hudis CA, Albanel J, Tong J, Tepler I, Currie V, et al. Dose-dense therapy with 1-h paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353-3361.
10. Perez E, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19:4216-4223.
11. Seidman AD, Berry D, Cirrincione C, Harris L, Dressler R, Muss H, et al. CALGB 9840: phase III study of weekly paclitaxel via 1-h infusion versus standard 3-h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004; 22:14S [abstract 512].
12. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with once-every-3-weeks paclitaxel. J Clin Oncol 2005; 23:5983-5992.
13. Miller AB, Hoogstraten B, Staquet M,Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
14. Simon S. Optimal two-stage design for phase II clinical trials. Controlled Clin Trials 1989; 10:1-10.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:475-481.
16. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. The Oncologist 2005; 10:370-381.
17. Twelves CJ, Dobbs NA, Aldhous A, Harper PG, Rubens RD, Richards MA. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 1991; 28:302-307.
18. French Epirubicin Study Group (FESG). A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 1988; 6:679-688.
19. Fargeot P, Bonneterre J, Roché H, Lortholary A, Campone M, Van Praagh I, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004; 22:4674-4682.
20. Marchetti P, Urien S, Antonini-Cappellini G, Ronzino G, Ficorella C. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hemat 2002; 44:S3-S13.
21. Seidman A. 'Will Weekly Work?' Seems to be soy ... . J Clin Oncol 2005; 23:5873-5874.
22. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005; 23:1951-1961.
23. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, et al. Anti-angiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65:2433-2440.
24. Nisticò C, Cognetti F, Frontini L, Barni S, Ferretti G, Bria E, et al. Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. Oncology 2005; 68:356-363.
25. Nistico C, Bria E, Agostara B, Barni S, Colella E, Frontini L, et al. Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study. Anticancer Drugs 2006; 17:345-351.
26. Piccart-Gebhart MJ. Mathematics and oncology: a match for life? J Clin Oncol 2003; 21:1425-1428.
27. Papaldo P, Lopez P, Marolla P, Cortesi E, Antimi M, Terzoli E, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:6908-6918.
28. Nistico C, Garufi C, Barni S, Frontini L, Galla DA, Giannarelli D, et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999; 10:937-942.
29. Wenzel C, Locker GJ, Pluschnig U, Zielinski CC, Rudas M, Oberhuber G, et al. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol 2002; 50:155-159.
30. Kohler U, Olbricht SS, Fuechsel G, Kettner E, Richter B, Ridwelski K. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study. Semin Oncol 1997; 24(5 Suppl 17):S17-40-S17-43.
31. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DH, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197-2205.
32. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 2005; 23:5117-5125.
33. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
34. Robert N, Leyland-Jones B, Asmar L, Belt R, Iglebodu D, Loesch D, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 2786-2792.
35. Forbes JF, Pienkowski T, Valero V, Eiermann W, Von Minckwitz G, Martin M, et al., on behalf of the BCIRG007 investigators. BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). J Clin Oncol 2006; 24:LBA516.